Module 2: Specialty Specific Guidance: Cardiology

This module will provide a thorough overview of challenges and benefits of, and indications for, using GLP-1 RAs in cardiology patients with an increased risk for a MACE and who are overweight or obese.
Alison L. Bailey, MD

Chief, Cardiology
Centennial Heart at Parkridge
Parkridge Medical Center
Chattanooga, TN

Alison L. Bailey, MD, FACC, FASPC, is chief of cardiology for Centennial Heart at Parkridge in Chattanooga, Tennessee and a Physician Director of Cardiovascular Disease for HCA Healthcare. Her clinical practice focuses on the prevention of cardiovascular disease, women’s cardiovascular care, and the diagnosis and treatment of heart failure. Her clinical practice incorporates nutrition, activity, and overall lifestyle changes for all patients to optimize cardiovascular health. She is passionate about medical education, improving cardiovascular health, and advocating for her colleagues and patients.

She currently serves as the Treasurer for the American Society of Preventive Cardiology, is a member of the ACC HeartPAC Executive Committee, and is the editor-in-chief of the American College of Cardiology’s Extended Learning (ACCEL) editorial board.

1.
DESCRIBE how GLP-1 receptor agonists align with cardiology-specific care priorities, such as cardiovascular risk reduction.
2.
INDIVIDUALIZE counseling and management approaches for GLP-1 receptor agonist therapy to address specialty-specific patient needs, such as reducing cardiovascular risk.